184 related articles for article (PubMed ID: 37978831)
21. Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation.
Vandenbriele C; Vanassche T; Peetermans M; Verhamme P; Peerlinck K
J Thromb Thrombolysis; 2014 Jul; 38(1):121-3. PubMed ID: 24202701
[TBL] [Abstract][Full Text] [Related]
22. D-dimer and its relationship to fibrinogen/fibrin degradation products (FDPs) in disorders associated with activation of coagulation or fibrinolytic systems.
Moresco RN; Vargas LC; Voegeli CF; Santos RC
J Clin Lab Anal; 2003; 17(3):77-9. PubMed ID: 12696076
[TBL] [Abstract][Full Text] [Related]
23. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review.
Eljilany I; Elzouki AN
Vasc Health Risk Manag; 2020; 16():455-462. PubMed ID: 33223833
[TBL] [Abstract][Full Text] [Related]
24. Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations.
Yamada S; Asakura H
Int J Hematol; 2021 Jan; 113(1):15-23. PubMed ID: 33175341
[TBL] [Abstract][Full Text] [Related]
25. Effect of sirolimus on coagulopathy of slow-flow vascular malformations.
Mack JM; Verkamp B; Richter GT; Nicholas R; Stewart K; Crary SE
Pediatr Blood Cancer; 2019 Oct; 66(10):e27896. PubMed ID: 31250546
[TBL] [Abstract][Full Text] [Related]
26. Peri-procedural Anticoagulation in Patients with Head and Neck Versus Extremity Venous Malformations.
Dharmarajan H; McCoy JL; Jabbour N; McCormick A; Xavier F; Correa D; Padia R
Laryngoscope; 2021 May; 131(5):1163-1167. PubMed ID: 33037831
[TBL] [Abstract][Full Text] [Related]
27. Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography.
Mack JM; Pierce CD; Richter GT; Spray BJ; Nicholas R; Lewis PS; Becton D; Crary SE
Pediatr Blood Cancer; 2021 Feb; 68(2):e28824. PubMed ID: 33211399
[TBL] [Abstract][Full Text] [Related]
28. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen.
Boisclair MD; Lane DA; Wilde JT; Ireland H; Preston FE; Ofosu FA
Br J Haematol; 1990 Apr; 74(4):471-9. PubMed ID: 2189490
[TBL] [Abstract][Full Text] [Related]
29. Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome.
Mazoyer E; Enjolras O; Laurian C; Houdart E; Drouet L
Clin Lab Haematol; 2002 Aug; 24(4):243-51. PubMed ID: 12181029
[TBL] [Abstract][Full Text] [Related]
30. Relevance of D-dimer testing in patients with venous malformations.
Maguiness S; Koerper M; Frieden I
Arch Dermatol; 2009 Nov; 145(11):1321-4. PubMed ID: 19917966
[No Abstract] [Full Text] [Related]
31. Angiogenic and prothrombotic markers in extensive slow-flow vascular malformations: implications for antiangiogenic/antithrombotic strategies.
Redondo P; Aguado L; Marquina M; Paramo JA; Sierra A; Sánchez-Ibarrola A; Martínez-Cuesta A; Cabrera J
Br J Dermatol; 2010 Feb; 162(2):350-6. PubMed ID: 19769632
[TBL] [Abstract][Full Text] [Related]
32. Prediction of venous malformations with localized intravascular coagulopathy with diffusion-weighted magnetic resonance imaging.
Razek AA; Ashmalla GA
Phlebology; 2019 Apr; 34(3):156-161. PubMed ID: 29720044
[TBL] [Abstract][Full Text] [Related]
33. Sclerotherapy with Adjunctive Stasis of Efflux (STASE) in Venous Malformations: Techniques and Strategies.
Legiehn GM
Tech Vasc Interv Radiol; 2019 Dec; 22(4):100630. PubMed ID: 31864535
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and Treatment of Venous Malformations. Consensus Document of the International Union of Phlebology (IUP): updated 2013.
Lee BB; Baumgartner I; Berlien P; Bianchini G; Burrows P; Gloviczki P; Huang Y; Laredo J; Loose DA; Markovic J; Mattassi R; Parsi K; Rabe E; Rosenblatt M; Shortell C; Stillo F; Vaghi M; Villavicencio L; Zamboni P;
Int Angiol; 2015 Apr; 34(2):97-149. PubMed ID: 24566499
[TBL] [Abstract][Full Text] [Related]
35. Pitfalls in the assessment of disseminated intravascular coagulation in patients on dabigatran.
Kanda GS; Ho WK; Rodrigues C; Bousounis A; Hogan C
Pathology; 2021 Aug; 53(5):623-627. PubMed ID: 33526243
[TBL] [Abstract][Full Text] [Related]
36. [Clinical use of D-dimer testing].
Lachâtre F; Gothot A
Rev Med Liege; 2007 Jan; 62(1):29-35. PubMed ID: 17343127
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary arterial hypertension in patients with slow-flow vascular malformations.
Rodríguez-Mañero M; Aguado L; Redondo P
Arch Dermatol; 2010 Dec; 146(12):1347-52. PubMed ID: 21173318
[TBL] [Abstract][Full Text] [Related]
38. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of D-dimer in outpatients: clinical value and specific features].
Vavilova TV; Vorob'eva IuK; Krupotkina IG; Mnuskina MM; Zherlitsina EA; Minkin SR
Klin Lab Diagn; 2009 Nov; (11):42-6. PubMed ID: 20050285
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with thrombotic complications in pediatric patients with vascular malformations.
Sepúlveda P; Zavala A; Zúñiga P
J Pediatr Surg; 2017 Mar; 52(3):400-404. PubMed ID: 27884452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
